A risk index for early node-negative breast cancer

British Journal of Surgery

Volumn 93, Issue 5, 2006, Pages 564-571

  Boyages, J ^a,c   Taylor, R ^a,b   Chua, B ^a   Ung, O ^a   Bilous, M ^a   Salisbury, E ^a   Wilcken, N ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c CANCER INSTITUTE NSW   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR;

ADJUVANT THERAPY; ADULT; AGED; BREAST CANCER; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODE EXCISION; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RISK ASSESSMENT;

EID: 33646482916     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.5207     Document Type: Conference Paper

References (22)

1. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-1467.
2. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352: 930-942.
3. Rosen PP, Groshen S. Factors influencing survival and prognosis in early breast carcinoma (T1 N0 M0-T1 N1 M0). Assessment of 644 patients with median follow-up of 18 years. Surg Clin North Am 1990; 70: 937-962.
4. Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman S. Pathological prognostic factors in stage 1 (T1 N0 M0) and stage II (T1 N1 M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J Clin Oncol 1989; 7: 1239-1251.
5. Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman S. A long-term follow-up study of survival in stage I (T1 N0 M0) and stage II (T1 N1 M0) breast carcinoma. J Clin Oncol 1989; 7: 355-366.
6. Quiet CA, Ferguson DJ, Weichselbaum RR, Hellman S. Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up. J Clin Oncol 1995; 13: 1144-1151.
7. Zujewski J, Liu ET. The 1998 St Gallen's Consensus Conference: an assessment. J Natl Cancer Inst 1998; 90: 1587-1589.
8. Boyages J, Chua B, Taylor R, Bilous M, Salisbury E, Wilcken N et al. Use of the St Gallen classification for patients with node-negative breast cancer may lead to overuse of adjuvant chemotherapy. Br J Surg 2002; 89: 789-796.
9. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 2001; 19: 3817-3827.
10. Fisher B, Slack NH. Number of lymph nodes examined and the prognosis of breast carcinoma. Surg Gynecol Obstet 1970; 131: 79-88.
11. Boyages J, Barraclough B, Middledorp J, Gorman D, Langlands AO. Early breast cancer: cosmetic and functional results after treatment by conservative techniques. ANZ J Surg 1988; 58: 111-121.
12. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer: a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957; 11: 359-377.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Soc 1958; 53: 457-481.
14. Cox DR. Regression models and life-tables. J R Stat Soc B 1972; 34: 187-220.
15. Ravdin PM, Clark GM. A practical application of neural network analysis for predicting outcome of individual breast cancer patients. Breast Cancer Res Treat 1992; 22: 285-293.
16. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992; 22: 207-219.
17. Clark GM, Hilsenbeck S, Osborne CK, Ravdin PM. A personal computer based program for providing outcome estimates and cooperative group trial eligibility for adjuvant therapy. University of Texas Health Science Center. Astro Proceedings 1995; 14: 96 (Abstract).
18. Osborne CK. Prognostic factors for breast cancer: have they met their promise? J Clin Oncol 1992; 10: 679-682.
19. Hilsenbeck SG, Ravdin PM, de Moor CA, Chamness GC, Osborne CK, Clark GM. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 1998; 52: 227-237.
20. Ravdin PM. Prognostic Factors in Breast Cancer. American Society of Clinical Oncology: Alexandria, VA, 1997; 217-227.
21. Ravdin PM. A computer program to assist in making breast cancer adjuvant therapy decisions. Semin Oncol 1996; 23(Suppl 2): 43-50.
22. Singh L, Wilson AJ, Baum M, Whimster WF, Birch IH, Jackson IM et al. The relationship between histological grade, oestrogen receptor status, events and survival at 8 years in the NATO ('Nolvadex') trial. Br J Cancer 1988; 57: 612-614.